

VMAT2 Inhibitors

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| | , , , | • | |
|---|-------------------------------------|---------------------------------|--|
| Member Name: | Prescriber Name: | | |
| HPP Member Number: | Fax: | Phone: | |
| Date of Birth: | Office Contact: | | |
| Member Primary Phone: | NPI: | PA PROMISe ID: | |
| Address: | Address: | | |
| City, State ZIP: | City, State ZIP: | | |
| Line of Business: ☐ Medicaid ☐ CHIP | Specialty Pharmacy (if applicable): | | |
| Drug Name: | Strength: | | |
| Quantity: | Refills: | | |
| Directions: | | | |
| Diagnosis Code: Diagnosis: | | | |
| HPP's maximum approval time is 12 months but may be less depending on the drug. | | | |
| • | | g on the thag. | |
| | | | |
| Please attach any pertinent medical history including lab | s and information for this me | mber that may support approval. | |
| Please answer the fol | lowing questions and sign. | | |
| Q1. Is this a request for continuation of therapy | with the requested agen | t? | |
| ☐ Yes | □No | | |
| | | | |
| Q2. Is patient being prescribed a vesicular monoamine transporter-2 (VMAT2) inhibitor by, or in | | | |
| consultation with, a neurologist or a psychiatrist? | | | |
| ☐ Yes | □No | | |
| _ | | | |
| Q3. Is the patient of an appropriate age according to Food and Drug Administration (FDA)-approved package labeling, compendia, or peer-reviewed medical literature? | | | |
| ☐ Yes | □No | | |
| | | | |
| Q4. Is there documentation that the patient has a diagnosis that is indicated in the Food and Drug Administration (FDA)-approved package labeling, OR is listed in nationally recognized compendia for the determination of medically-accepted indications for off-label uses for the prescribed agent? | | | |
| ☐ Yes | □ No | | |
| Q5. Does the patient have a contraindication to the prescribed agent? | | | |

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



VMAT2 Inhibitors

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| Member Name: | Prescriber Name: | |
|---|------------------|--|
| □Yes | □No | |
| Q6. Does the patient have a history of a prior suicide attempt, bipolar disorder, or major depressive disorder? | | |
| ☐ Yes | □ No | |
| Q7. Has the patient had a mental health evaluation performed? | | |
| □ Yes | □No | |
| Q8. Has the patient been evaluated within the previous 6 months and treated by a psychiatrist? | | |
| ☐ Yes | □No | |
| Q9. Is the patient being treated for a diagnosis of tardive dyskinesia? | | |
| □Yes | □No | |
| Q10. Was the patient assessed for and determined to have no other causes of involuntary movement? | | |
| □Yes | □ No | |
| Q11. Was the patient evaluated for appropriateness of dose reduction of dopamine receptor blocking agents? | | |
| ☐ Yes | □ No | |
| Q12. Is there documentation of tardive dyskinesia severity using a validated scale or assessment of impact on daily function? | | |
| ☐ Yes | □ No | |
| Q13. Is this a request for a non-preferred vesicular monoamine transporter-2 (VMAT2) inhibitor? | | |
| □Yes | □ No | |



VMAT2 Inhibitors

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| Member Name: | Prescriber Name: | |
|--|------------------|--|
| Q14. Is there documentation of therapeutic failure or intolerance to the preferred vesicular monoamine transporter-2 (VMAT2) inhibitors? | | |
| ☐ Yes | □ No | |
| Q15. Does the patient have a diagnosis of chorea? | | |
| ☐ Yes | □ No | |
| Q16. Has the patient experienced a clinical benefit from treatment with the prescribed agent based on the prescriber's clinical judgment? | | |
| ☐ Yes | □ No | |
| Q17. Does the patient have a diagnosis of tardive dyskinesia? | | |
| ☐ Yes | □ No | |
| Q18. Has the patient experienced an improveme a validated scale or improvement in daily functio | | |
| ☐ Yes | □ No | |
| Q19. Does the patient have a contraindication to the prescribed agent? | | |
| ☐ Yes | □ No | |
| Q20. Has the patient been re-evaluated and treated for new onset or worsening symptoms of depression and determined to continue to be a candidate for treatment with the prescribed agent? | | |
| ☐ Yes | □ No | |
| Q21. Additional Information: | | |
| | | |
| Prescriber Signature | Date | |

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



VMAT2 Inhibitors

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| Member Name: Prescriber Name: |
|-------------------------------|
|-------------------------------|

v2025